Iovance Biotherapeutics (HAM:2LB) Cyclically Adjusted FCF per Share: €-1.36 (As of Mar. 2026)


HAM:2LB Iovance Biotherapeutics Inc HAM:2LB
44 GF Score
Price €3.78
GF Value €17.09
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics Cyclically Adjusted FCF per Share?

Iovance Biotherapeutics HAM:2LB +2.44% 44 Cyclically Adjusted FCF per Share is €-1.36 as of Mar. 2026. GuruFocus rates HAM:2LB with a GF Score™ of 44/100 and a GF Value™ of €17.09 (Possible Value Trap). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Iovance Biotherapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.163. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.36 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -5.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Iovance Biotherapeutics was 13.40% per year. The lowest was -7.40% per year. And the median was 3.40% per year.

As of today (2026-07-07), Iovance Biotherapeutics's current stock price is €3.775. Iovance Biotherapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-1.36. Iovance Biotherapeutics's Cyclically Adjusted Price-to-FCF of today is .


Iovance Biotherapeutics  (HAM:2LB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Iovance Biotherapeutics Cyclically Adjusted FCF per Share Related Terms


Iovance Biotherapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Iovance Biotherapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iovance Biotherapeutics Cyclically Adjusted FCF per Share Chart

Iovance Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.38

Iovance Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.38 -1.36

HAM:2LB vs SNDX, GLUE, TYRA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Iovance Biotherapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Cyclically Adjusted Price-to-FCF falls into.


HAM:2LB
44GF Score
Iovance Biotherapeutics Inc HAM:2LB
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iovance Biotherapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Iovance Biotherapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.163/330.2130*330.2130
=-0.163

Current CPI (Mar. 2026) = 330.2130.

Iovance Biotherapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.066 241.018 -0.090
201609 -0.195 241.428 -0.267
201612 -0.197 241.432 -0.269
201703 -0.294 243.801 -0.398
201706 -0.250 244.955 -0.337
201709 -0.288 246.819 -0.385
201712 -0.242 246.524 -0.324
201803 -0.172 249.554 -0.228
201806 -0.231 251.989 -0.303
201809 -0.256 252.439 -0.335
201812 -0.235 251.233 -0.309
201903 -0.215 254.202 -0.279
201906 -0.252 256.143 -0.325
201909 -0.318 256.759 -0.409
201912 -0.408 256.974 -0.524
202003 -0.471 258.115 -0.603
202006 -0.277 257.797 -0.355
202009 -0.338 260.280 -0.429
202012 -0.482 260.474 -0.611
202103 -0.417 264.877 -0.520
202106 -0.343 271.696 -0.417
202109 -0.368 274.310 -0.443
202112 -0.346 278.802 -0.410
202203 -0.493 287.504 -0.566
202206 -0.495 296.311 -0.552
202209 -0.416 296.808 -0.463
202212 -0.462 296.797 -0.514
202303 -0.461 301.836 -0.504
202306 -0.425 305.109 -0.460
202309 -0.334 307.789 -0.358
202312 -0.313 306.746 -0.337
202403 -0.437 312.332 -0.462
202406 -0.322 314.175 -0.338
202409 -0.182 315.301 -0.191
202412 -0.243 315.605 -0.254
202503 -0.315 319.799 -0.325
202506 -0.194 322.561 -0.199
202509 -0.210 324.800 -0.213
202512 -0.130 324.054 -0.132
202603 -0.163 330.213 -0.163

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-1.36 mean?
Iovance Biotherapeutics (HAM:2LB) has a Cyclically Adjusted FCF per Share of €-1.36 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Iovance Biotherapeutics and its competitors.
Is Iovance Biotherapeutics' Cyclically Adjusted FCF per Share too high?
Iovance Biotherapeutics' current Cyclically Adjusted FCF per Share is €-1.36. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Cyclically Adjusted FCF per Share compare to SNDX and GLUE?
Iovance Biotherapeutics' Cyclically Adjusted FCF per Share of €-1.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Iovance Biotherapeutics and its competitors. Iovance Biotherapeutics's current Cyclically Adjusted FCF per Share is €-1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (HAM:2LB) is currently considered Possible Value Trap. The stock's GF Value™ is €17.09, compared to a current price of €3.78 — trading 77.9% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-1.36. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Iovance Biotherapeutics (HAM:2LB), the current Cyclically Adjusted FCF per Share is €-1.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iovance Biotherapeutics (HAM:2LB) Overvalued in 2026?

Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued. The current stock price of €3.78 is trading 77.9% below its estimated GF Value™ of €17.09. GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.

Key valuation signals for HAM:2LB:

  • Cyclically Adjusted FCF per Share: €-1.36
  • GF Value™: €17.09 vs. price of €3.78 (77.9% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the HAM:2LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score

Get the complete analysis for HAM:2LB

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.78
Price
€17.09
GF Value